WO2018094035A3 - Ligand ionophore conjugates - Google Patents

Ligand ionophore conjugates Download PDF

Info

Publication number
WO2018094035A3
WO2018094035A3 PCT/US2017/061997 US2017061997W WO2018094035A3 WO 2018094035 A3 WO2018094035 A3 WO 2018094035A3 US 2017061997 W US2017061997 W US 2017061997W WO 2018094035 A3 WO2018094035 A3 WO 2018094035A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
ligand
ionophore
ionophore conjugates
therapeutic agent
Prior art date
Application number
PCT/US2017/061997
Other languages
French (fr)
Other versions
WO2018094035A2 (en
Inventor
Philip Stewart Low
Andrea L. KASINSKI
Loganathan RANGASAMY
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Priority to EP17871348.3A priority Critical patent/EP3541403A4/en
Priority to JP2019526213A priority patent/JP7116728B2/en
Priority to CN201780083686.7A priority patent/CN110167577A/en
Publication of WO2018094035A2 publication Critical patent/WO2018094035A2/en
Publication of WO2018094035A3 publication Critical patent/WO2018094035A3/en
Priority to US16/413,940 priority patent/US20190298843A1/en
Priority to JP2022121625A priority patent/JP2022166047A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention described herein pertains to ligand-ionophore conjugates, that may also comprise a linked therapeutic agent or imaging agent, and pharmaceutical compositions containing the conjugates. Also described are methods of using the conjugates for increasing the endosomal accumulation and escape of a therapeutic agent, or an imaging agent.
PCT/US2017/061997 2015-05-11 2017-11-16 Ligand ionophore conjugates WO2018094035A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP17871348.3A EP3541403A4 (en) 2016-11-16 2017-11-16 Ligand ionophore conjugates
JP2019526213A JP7116728B2 (en) 2016-11-16 2017-11-16 ligand ionophore conjugate
CN201780083686.7A CN110167577A (en) 2016-11-16 2017-11-16 Ligand ion carrier conjugate
US16/413,940 US20190298843A1 (en) 2015-05-11 2019-05-16 Ligand ionophore conjugates
JP2022121625A JP2022166047A (en) 2016-11-16 2022-07-29 Ligand-ionophore conjugates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662422922P 2016-11-16 2016-11-16
US62/422,922 2016-11-16
US201762478063P 2017-03-29 2017-03-29
US62/478,063 2017-03-29

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US15/572,985 Continuation-In-Part US10406238B2 (en) 2015-05-11 2016-05-11 Ligand ionophore conjugates
PCT/US2016/031738 Continuation-In-Part WO2016183131A1 (en) 2015-05-11 2016-05-11 Ligand ionophore conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/413,940 Continuation-In-Part US20190298843A1 (en) 2015-05-11 2019-05-16 Ligand ionophore conjugates

Publications (2)

Publication Number Publication Date
WO2018094035A2 WO2018094035A2 (en) 2018-05-24
WO2018094035A3 true WO2018094035A3 (en) 2018-06-28

Family

ID=62146794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/061997 WO2018094035A2 (en) 2015-05-11 2017-11-16 Ligand ionophore conjugates

Country Status (4)

Country Link
EP (1) EP3541403A4 (en)
JP (2) JP7116728B2 (en)
CN (1) CN110167577A (en)
WO (1) WO2018094035A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112010862B (en) * 2020-10-23 2021-03-30 南京诺源医疗器械有限公司 Active targeting folic acid receptor near-infrared fluorescent molecule and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006041A2 (en) * 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
WO2012112440A2 (en) * 2011-02-14 2012-08-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fluorescent potassium ion sensors
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
WO2015130997A1 (en) * 2014-02-26 2015-09-03 Gdovin Matthew Nitrobenzaldehyde proton release for manipulation of cellular acidosis
US20160160220A1 (en) * 2014-09-24 2016-06-09 University Of Cincinnati Methods and Compositions for Treating Autoimmune Disorders by Targeting Kv1.3 Ion Channels with Functionalized Lipid-Derived Nanovesicles
WO2016183131A1 (en) * 2015-05-11 2016-11-17 Purdue Research Foundation Ligand ionophore conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2564839B1 (en) * 1984-05-23 1986-11-14 Sanofi Sa CONJUGATES COMBINING BY COVALENT BINDING A MONOVALENT CARBOXYLIC IONOPHORE AND A MACROMOLECULE AND THEIR USE AS POTENTIALIZERS OF IMMUNOTOXINS
CA1314245C (en) * 1984-05-23 1993-03-09 Franz Jansen Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators
SI2187965T1 (en) * 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Psma binding ligand-linker conjugates and methods for using
US20110288152A1 (en) * 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US20120022245A1 (en) * 2008-10-17 2012-01-26 Purdue Research Foundation Folate targeting of nucleotides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
WO2007006041A2 (en) * 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
WO2012112440A2 (en) * 2011-02-14 2012-08-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fluorescent potassium ion sensors
WO2015130997A1 (en) * 2014-02-26 2015-09-03 Gdovin Matthew Nitrobenzaldehyde proton release for manipulation of cellular acidosis
US20160160220A1 (en) * 2014-09-24 2016-06-09 University Of Cincinnati Methods and Compositions for Treating Autoimmune Disorders by Targeting Kv1.3 Ion Channels with Functionalized Lipid-Derived Nanovesicles
WO2016183131A1 (en) * 2015-05-11 2016-11-17 Purdue Research Foundation Ligand ionophore conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUCHS ET AL.: "Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell -like KG -1a cells", BIOCHEM BIOPHYS RES COMMUN, vol. 394, no. 4, 27 March 2010 (2010-03-27), pages 1098 - 1104, XP027009698 *

Also Published As

Publication number Publication date
CN110167577A (en) 2019-08-23
EP3541403A2 (en) 2019-09-25
EP3541403A4 (en) 2020-08-12
JP7116728B2 (en) 2022-08-10
JP2022166047A (en) 2022-11-01
WO2018094035A2 (en) 2018-05-24
JP2019535719A (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MA41937A (en) CONJUGATES OF MEDICINAL PRODUCTS INCLUDING ANTIBODIES AGAINST CLAUDINE 18.2
WO2015179559A3 (en) Pyrazole compounds and methods of making and using same
SA518400356B1 (en) Arginase inhibitors and their therapeutic applications
WO2016149401A3 (en) Piperazine carbamates and methods of making and using same
WO2015168019A3 (en) Anti-ptk7 antibody-drug conjugates
WO2016100619A3 (en) Treatment and diagnosis of cancer
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
WO2015164392A3 (en) Novel antii-rnf43 antibodies and methods of use
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2017016802A (en) Pharmaceutical formulations.
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
PH12019502676A1 (en) Moisturizing topical preparation
WO2016130581A8 (en) Combination cancer therapy
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
WO2016181220A3 (en) Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof
MX2019001634A (en) Amide compounds, pharmaceutical compositions thereof, and methods of using the same.
WO2017075171A3 (en) Pamam dendrimer based cest imaging agents and uses thereof
PH12018501758A1 (en) Oritavancin formulations
MX2019008338A (en) Pharmaceutical composition containing sulglycotide or pharmaceutically acceptable salt thereof for preventing or treating dry eye.
WO2015001541A3 (en) Pharmaceutical film composition
EP3453390A4 (en) Polymerized drug-containing pharmaceutical composition
EP3401685A4 (en) Diagnostic agent and medicine comprising adamts13 as main ingredient
WO2018094035A3 (en) Ligand ionophore conjugates
IL274588A (en) Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease
SG11202010792TA (en) Improved pharmaceutical formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17871348

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019526213

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017871348

Country of ref document: EP

Effective date: 20190617